

Cite this: *Chem. Sci.*, 2017, 8, 7689

# A mitochondrial-targeted prodrug for NIR imaging guided and synergetic NIR photodynamic-chemo cancer therapy†

Hong-Wen Liu,<sup>a</sup> Xiao-Xiao Hu,<sup>†a</sup> Ke Li,<sup>a</sup> Yongchao Liu,<sup>a</sup> Qiming Rong,<sup>a</sup> Longmin Zhu,<sup>a</sup> Lin Yuan,<sup>a</sup> Feng-Li Qu,<sup>a</sup> Xiao-Bing Zhang<sup>\*,a</sup> and Weihong Tan<sup>a</sup>

Nontoxic prodrugs, especially activated by tumor microenvironment, are urgently required for reducing the side effects of cancer therapy. And combination of chemo-photodynamic therapy prodrugs show effectively synergetic therapeutic efficiency, however, this goal has not been achieved in a single molecule. In this work, we developed a mitochondrial-targeted prodrug PNPS for near infrared (NIR) fluorescence imaging guided and synergetic chemo-photodynamic precise cancer therapy for the first time. PNPS contains a NIR photosensitizer (NPS) and an anticancer drug 5'-deoxy-5-fluorouridine (5'-DFUR). These two parts are linked and caged through a bisboronate group, displaying no fluorescence and very low cytotoxicity. In the presence of H<sub>2</sub>O<sub>2</sub>, the bisboronate group is broken, resulting in activation of NPS for NIR photodynamic therapy and activation of 5'-DFUR for chemotherapy. The activated NPS can also provide a NIR fluorescence signal for monitoring the release of activated drug. Taking advantage of the high H<sub>2</sub>O<sub>2</sub> concentration in cancer cells, PNPS exhibits higher cytotoxicity to cancer cells than normal cells, resulting in lower side effects. In addition, based on its mitochondrial-targeted ability, PNPS exhibits enhanced chemotherapy efficiency compare to free 5'-DFUR. It also demonstrated a remarkably improved and synergistic chemo-photodynamic therapeutic effect for cancer cells. Moreover, PNPS exhibits excellent tumor microenvironment-activated performance when intravenously injected into tumor-bearing nude mice, as demonstrated by *in vivo* fluorescence imaging. Thus, PNPS is a promising prodrug for cancer therapy based on its tumor microenvironment-activated drug release, synergistic therapeutic effect and "turn-on" NIR imaging guide.

Received 8th August 2017  
Accepted 11th September 2017

DOI: 10.1039/c7sc03454g

rsc.li/chemical-science

## Introduction

Significant advances in cancer diagnosis and therapy have been made in the past years, but there still remain several barriers for improving effectiveness and avoiding severe side effects.<sup>1–5</sup> This highlights the need to develop anticancer agents for effectively and selectively killing tumor cells without affecting normal tissues. Photodynamic therapy (PDT), driven by activating photosensitizers (PSs) to generate reactive oxygen species (ROS),

generally singlet oxygen for cancer cell killing, is considered to be a safe, minimally invasive treatment.<sup>6,7</sup> Highly selective photosensitizers are still desirable for accurately localizing and activatable prodrug to minimize side effects and realize more efficient therapeutic outcome. Recently, some activatable PSs have been developed for further minimizing the side effects of PDT.<sup>8,9</sup> The design strategy is generally based on the concept that the prequenched fluorescence and inhibited phototoxicity of the PS which can be restored once a specific trigger is able to separate the quencher or energy acceptor from the vicinity of the PS.<sup>10,11</sup> Moreover, the near infrared (NIR) PSs are desired for PDT, because NIR photons can deeply penetrate the skin and underlying tissue with low damage to the biological samples and minimal background interference.<sup>12–14</sup> Therefore, it's very significant to develop activatable NIR PSs. On the other hand, chemotherapy is one of the most important modalities of cancer treatment. 5-Fluorouracil (5-FUra) has been used in the treatment of a variety of neoplastic diseases. 5'-Deoxy-5-fluorouridine (5'-DFUR), a prodrug of 5-FUra, can be converted to 5-FUra by the thymidine phosphorylase, which is more abundant in tumors than in normal tissues except for the liver

<sup>a</sup>Molecular Science and Biomedicine Laboratory, State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Life Sciences, Aptamer Engineering Center of Hunan Province, Hunan University, Changsha, 410082, P. R. China. E-mail: xbzhang@hnu.edu.cn

<sup>b</sup>The Key Laboratory of Life-Organic Analysis, College of Chemistry and Chemical Engineering, Qufu Normal University, Qufu, Shandong, 273165, P. R. China

<sup>c</sup>Key Laboratory of Environmentally Friendly Chemistry and Applications of Ministry of Education, College of Chemistry, Xiangtan University, Xiangtan 411105, P. R. China

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c7sc03454g


‡ These authors contributed equally to this work.



of humans.<sup>15</sup> The combination of PDT and chemotherapy with different therapeutic mechanisms has also been proved effective in improving the therapeutic efficiency,<sup>16</sup> which has been achieved mainly *via* co-encapsulated an anticancer drug and a PS in nanocarriers.<sup>17,18</sup> In addition, since the extremely short half-life (<40 ns) and small radius of action (<20 nm) of singlet oxygen (<sup>1</sup>O<sub>2</sub>) in biological systems,<sup>19</sup> direct delivering of PS to hypersensitive subcellular organelles will greatly enhance the PDT efficiency.<sup>20–22</sup> Mitochondria are vital intracellular organelles that play valuable roles in energy production, ROS generation, cellular signalling and regulate apoptosis. Owing to the essential and fatal role of mitochondria, several mitochondrial-targeted anti-cancer drugs have been developed to expect optimal therapeutic efficiency.<sup>23,24</sup> Many evidences also indicate that the damage of mitochondria is the main pathway for PDT-treated cell apoptosis.<sup>20</sup> Thus, mitochondrion is the ideal subcellular target for cancer therapy.

The design of molecular fluorescent probe provides the strategy for developing theranostic prodrugs for targeted and image-guided combination cancer therapy.<sup>25</sup> Fluorescent imaging can provide realtime informations about where, when, and how the prodrugs are delivered and activated *in vivo*.<sup>26</sup> Generally, in such theranostic systems, masked anticancer drugs and imaging reagents are conjugated by tumor-sensitive linkers.<sup>27</sup> Once in the tumor microenvironments, the tumor-sensitive linkers can be broken by tumor over express species, such as low pH,<sup>28</sup> high reactive oxygen species level (including H<sub>2</sub>O<sub>2</sub>),<sup>29–31</sup> high expressed enzymes,<sup>32–34</sup> and high glutathione (GSH) concentration,<sup>26,35–38</sup> resulting in the release of the anti-cancer drugs and the activation of the imaging reagents. However, most of previous theranostic drugs do not realize combination of PDT and chemotherapy in a single molecule, which encouraged us to explore molecular theranostic probes with multi-function, including NIR PDT, chemotherapy, subcellular targeting and NIR fluorescence for real-time monitoring the therapeutic effect.

In this work, we developed a mitochondrial-targeted prodrug **PNPS** for NIR fluorescence imaging guided and synergetic chemo-photodynamic precise cancer therapy for the first time. **PNPS** is composed of two moieties and a specific recognition linker as shown in Scheme 1. The first moiety is a NIR fluorescent monitor **NPS**, of which its essential properties of NIR fluorescence and phototoxicity can be countered, yes reversed, by caging its hydroxyl group, act as a prodrug for PDT. Meanwhile, this **NPS** is preferably localized in mitochondria, due to its lipophilic quaternary ammonium salt structure.<sup>39</sup> The second component is an anticancer drug 5'-DFUR. The former two parts are linked and caged through a H<sub>2</sub>O<sub>2</sub>-sensitive bisboronate group, displaying no fluorescence signal and therapeutic effect. In the presence of H<sub>2</sub>O<sub>2</sub>, the bisboronate group is broken, resulting in releasing the free **NPS** for NIR PDT and free 5'-DFUR for chemotherapy. The activated **NPS** can also provide a NIR fluorescence signal for monitoring the release of the activated drugs. Taking advantages of the high H<sub>2</sub>O<sub>2</sub> concentration in cancer cells, **PNPS** exhibited higher cytotoxicity to cancer cells than normal cells, resulting in lower side effects. In addition, based on its mitochondrial-targeted ability, **PNPS**



Scheme 1 Design of theranostic prodrug **PNPS** and proposed activation mechanism.


exhibited enhanced chemotherapy efficiency compare to free 5'-DFUR. Moreover, effective chemo-photodynamic combined therapy effects in cancer cells was observed. The *in vitro* and *in vivo* prodrug release was visualized by *in situ* generated NIR fluorescence. These favorable features of tumor microenvironment-activated ability, effective synergistic thertic effect and NIR fluorescence monitoring of the drug release make **PNPS** a promising prodrug.

## Results and discussion

We first developed a novel NIR photosensitizer **NPS**, which shows the maximum excitation and emission wavelength at 680 nm and 710 nm, respectively. Since activatable photosensitizers share similar activation mechanisms with activatable fluorophores, the inherent fluorescence of **NPS** is prohibited accompany with inhibited phototoxicity, when the hydroxyl group of **NPS** is caged. Based on the molecular probe design strategy, we hypothesized to develop a subcellular targeted molecular theranostic prodrug with multi-function, such as fluorescence imaging, PDT, chemotherapy, and real-time monitoring of the therapeutic effect. H<sub>2</sub>O<sub>2</sub> was chosen as the target for its high sensitivity and specificity toward the boronate moiety and intrinsic enhancement of H<sub>2</sub>O<sub>2</sub> levels inside the tumor cell.<sup>40</sup> It was easy to obtain prodrug **NPS-H<sub>2</sub>O<sub>2</sub>** by attaching the H<sub>2</sub>O<sub>2</sub> recognition group (benzoboric acid) to the hydroxyl group of **NPS**. And then, taking the advantage of the reaction between benzoboric acid and pinaacol (5'-DFUR contains pinaacol group), we obtained the final theranostic prodrug **PNPS**. The synthetic route for **PNPS** was depicted in Fig. S1.† And characterizations of all the new compounds are described in the ESI in detail.†

To verify that H<sub>2</sub>O<sub>2</sub> was able to cleave the boronate moiety of prodrug **PNPS** and consequently activate the NIR fluorophore, a chemical transformation experiment of **PNPS** was performed in the presence of H<sub>2</sub>O<sub>2</sub> under physiological conditions and monitored by UV-vis and fluorescence spectroscopy. In the UV-vis spectrum as shown in Fig. 1A, **PNPS** showed a strong





**Fig. 1** (A) Absorption and (B) fluorescence emission spectra of PNPS (5  $\mu\text{M}$ ) with different concentration  $\text{H}_2\text{O}_2$  in aqueous solution (PBS/DMSO = 19 : 1, v/v, 10 mM, pH = 7.4). Inset (A) photos of PNPS solution before (left) and after (right) addition of  $\text{H}_2\text{O}_2$ . (C) Calibration curve of PNPS to  $\text{H}_2\text{O}_2$ , the curve was plotted with the fluorescence intensity at 710 nm vs.  $\text{H}_2\text{O}_2$  concentration. (D) A plot of fluorescence intensity at 710 nm of PNPS vs. the reaction time in the presence of varied concentrations of  $\text{H}_2\text{O}_2$ .  $\lambda_{\text{ex}} = 680 \text{ nm}$ .


absorption peak at  $\lambda_{\text{max}} = 600 \text{ nm}$ . The absorption peak showed a red shift after addition of  $100 \mu\text{M}$   $\text{H}_2\text{O}_2$ , accompanied by a distinct color change from blue to blue-green (Fig. 1A inset). As shown in Fig. 1B, PNPS exhibited weak fluorescence centered at 710 nm, and gradual addition of  $\text{H}_2\text{O}_2$  up to 0–150  $\mu\text{M}$  to a solution of PNPS induced the increase of fluorescence intensity. The fluorescence intensity at 710 nm increased by 34.3-fold upon reaction with 150  $\mu\text{M}$   $\text{H}_2\text{O}_2$  for 30 min (Fig. 1C). Meanwhile, its intensity increased linearly with the concentration of  $\text{H}_2\text{O}_2$  ranging from 5 to 40  $\mu\text{M}$  (Fig. S2†). The catalytic efficiency of  $\text{H}_2\text{O}_2$  toward the PNPS was assessed. Fluorescence kinetic curves of  $\text{H}_2\text{O}_2$  at varied concentrations (0, 20, 100  $\mu\text{M}$ ) reacting with PNPS were depicted in Fig. 1D. As was shown, a higher concentration of  $\text{H}_2\text{O}_2$  could induce faster cleavage reaction and therefore result in increased fluorescence intensity. The fluorescence signal of the reaction system could reach a plateau in about 20 min. Meanwhile, in the absence of  $\text{H}_2\text{O}_2$ , testing the generation of a false positive signal by spontaneous hydrolysis, gave no detectable signal increase, even over 12 h (Fig. S3†), demonstrating that PNPS was stable in the reaction system. These results demonstrated that after reaction with  $\text{H}_2\text{O}_2$ , PNPS was efficiently activated and the released NPS could provide a turn-on NIR fluorescence signal for drug release and therapeutic efficacy monitoring.

The selectivity of prodrug PNPS for  $\text{H}_2\text{O}_2$  over other biologically relevant ROS species, metal ions, amino acids and proteins was evaluated. As shown in Fig. S4A,† no significant changes in fluorescence intensity were observed upon addition of the other ROS species, metal ions, amino acids and proteins to prodrug PNPS. The pH effect on the  $\text{H}_2\text{O}_2$ -induced fluorescence changes of PNPS was also investigated. As shown in Fig. S4B,† PNPS remained stable and emitted a weak fluorescence within 4.0–9.0 pH range. After treatment by 25  $\mu\text{M}$  of

$\text{H}_2\text{O}_2$ , the fluorescence at 710 nm was activated and reached saturation in the 7.4–8.0 pH range. The above results indicated that prodrug PNPS can be applied as a  $\text{H}_2\text{O}_2$ -activated theranostic prodrug under physiological pH condition with high selectivity.

To confirm the fluorescence response mechanism, the reaction products of PNPS with  $\text{H}_2\text{O}_2$  were analyzed by HPLC and HRMS. As illustrated in Fig. S5,† pure PNPS showed a unique peak with retention time at about 5.36 min, and compound NPS exhibited a peak at about 6.25 min. After PNPS incubation with  $\text{H}_2\text{O}_2$  for 30 min, a new peak at 6.25 min corresponding to compound NPS was clearly observed, and the peak corresponding to PNPS was sharply decreased. Moreover, in the ESI-HRMS (positive ion mode) spectrum of PNPS incubated with  $\text{H}_2\text{O}_2$  for 30 min, the peaks of NPS and 5'-DFUR were found at  $m/z$  464.1065 and 269.0462 respectively (Fig. S6†). These results demonstrated that the  $\text{H}_2\text{O}_2$  cleaved recognition site, then PNPS was activated and free NPS and 5'-DFUR were released.

On the basis of the positive results showing  $\text{H}_2\text{O}_2$ -activated release of active drug and concurrent fluorescence enhancement, PNPS was next tested in cultured cells. Cellular fluorescence imaging of PNPS were investigated in four different cell lines, HeLa, HepG2, HCT116 and HL7702 cells. HeLa, HepG2 and HCT116 cancer cells were pretreated with prodrug PNPS (5  $\mu\text{M}$ ) for different time, then fluorescence imaging were carried out. The increased fluorescence intensity of HeLa, HepG2 and HCT116 cells indicated the efficient activation of theranostic PNPS by endogenous  $\text{H}_2\text{O}_2$  in the tumor cells without any external inducer (Fig. 2A and S7–S9†). In addition, HeLa cells pretreated with exogenous  $\text{H}_2\text{O}_2$  for 0.5 h and then incubated with PNPS for another 0.5 h, the fluorescence intensity dramatically increased. The cellular activation of PNPS



**Fig. 2** Cellular fluorescence images of prodrug PNPS-treated HeLa (A) and HL7702 (B) cells. The cells were incubated with PNPS (5  $\mu\text{M}$ ) for 0.5 h, 1 h and 2 h, respectively, or the cells were pretreated with  $\text{H}_2\text{O}_2$  (100  $\mu\text{M}$ ) for 0.5 h and then incubated with PNPS for another 0.5 h. (C) Relative pixel intensity ( $n = 3$ ) from images (A and B). The pixel intensity from image (A) 2 h is defined as 1.0. Flow cytometric analysis of PNPS (5  $\mu\text{M}$ ) fluorescence after incubated with HeLa (D) or HL7702 (E) cells for different time; or cells incubated with PNPS for 0.5 h and  $\text{H}_2\text{O}_2$  (100  $\mu\text{M}$ ) for another 0.5 h.  $\lambda_{\text{ex}} = 635 \text{ nm}$ ,  $\lambda_{\text{em}} = 680\text{--}750 \text{ nm}$ .



were further confirmed by flow cytometry analysis (Fig. 2D). Similar phenomena were also observed in HepG2 cells (Fig. S8<sup>†</sup>), and the activation performance of **PNPS** in HepG2 after incubated for 2 h is 10% higher than that for HeLa cells calculated from the results of flow cytometry. These results indicated that the oxidation of boronate moiety of theranostic **PNPS** generated fluorescence enhancement, depending upon amount of intracellular  $\text{H}_2\text{O}_2$ , as depicted in Scheme 1. Normal HL-7702 cells were also incubated with prodrug **PNPS** for an examination of the effect of  $\text{H}_2\text{O}_2$  on the bioactivity of **PNPS**. Very weak fluorescence signals were observed in HL-7702 cells by confocal microscopy after incubating with **PNPS** for 0.5 h, 1 h or 2 h (Fig. 2B). However, after pretreated with  $100 \mu\text{M}$   $\text{H}_2\text{O}_2$  for 0.5 h, a strong fluorescent enhancement was observed in HL-7702 cells. The flow cytometry analysis results also confirmed that **PNPS** kept inactivated in HL-7702 cells (Fig. 2E). These results demonstrated that prodrug **PNPS** showed cancer cells-targeted activated ability.

Furthermore, mitochondrial localization of activated prodrug **PNPS** was investigated by colocalization experiments using a commercialized mitochondria fluorescent tracker, MitoTracker Green. As shown in Fig. 3 and S10,<sup>†</sup> the fluorescence signal that was ascribed to **PNPS** colocalized well with the MitoTracker (Pearson's correlation factor is 0.965, 0.943 and 0.958 for HeLa cells, HepG2 cells and HCT116 cells respectively), due to its lipophilic quaternary ammonium salt structure. Further experiments were carried out to demonstrate that most **PNPS** molecules will locate in mitochondria before reaction with cytoplasm  $\text{H}_2\text{O}_2$ , with the results showed in Fig S11.<sup>†</sup> This is mainly because the **PNPS** molecular can fast diffuse into cells and target mitochondria (within 10 min) before reaction with relatively low concentration cytoplasm  $\text{H}_2\text{O}_2$ . These results demonstrated the outstanding mitochondrial-targeting ability of **PNPS**, which may help improve the therapeutic effect.

The  $^1\text{O}_2$  generation of **PNPS** in buffer solution in the present of  $\text{H}_2\text{O}_2$  upon light irradiation was studied using 9, 10-diphenylanthracene (DPHA)<sup>41</sup> and fluorescent probe MNAH<sup>42</sup> as indicators. DPHA is a  $^1\text{O}_2$  indicator, whose absorbance decreases upon interaction with  $^1\text{O}_2$ . In the presence of  $\text{H}_2\text{O}_2$ , when incubating DPHA with **PNPS** upon white light irradiation, the absorbance of DPHA decreased gradually (Fig. S12A<sup>†</sup>). Meanwhile, pretreated **PNPS** with  $\text{H}_2\text{O}_2$  and then incubated with fluorescent probe MNAH upon white light irradiation, the fluorescence of MNAH increased gradually (Fig. S13A<sup>†</sup>). But in

the absence of  $\text{H}_2\text{O}_2$ , the absorbance of DPHA or the fluorescence of MNAH showed limited changes (Fig. S12B and S13B<sup>†</sup>). And the compared results were shown in the Fig. 4A and Fig. 4B, obvious difference could be observed between those whether pretreated with  $\text{H}_2\text{O}_2$ . These results demonstrated that **PNPS** could efficiently generate  $^1\text{O}_2$  in buffer solution after activated by  $\text{H}_2\text{O}_2$ , indicated its activable phototoxicity. The  $^1\text{O}_2$  generation of **PNPS** in cells upon light irradiation was studied using 2',7'-dichlorofluorescein diacetate (DCF-DA) as a cell-permeable probe. DCF-DA is nonfluorescent but can be oxidized by  $^1\text{O}_2$  to yield highly fluorescent 2',7'-dichlorofluorescein (DCF). As shown in Fig. 4C, strong green fluorescence could only be observed when the cells were treated with **PNPS** for 2 h followed by light irradiation. The results confirmed the  $^1\text{O}_2$  generation by activated **PNPS** in live HeLa cells upon light irradiation.

We then investigated the ability of prodrug **PNPS** to selectively target cancer cells by measuring its cytotoxicity to HeLa, HepG2 and HL-7702 cells. MTS assays were used to study cytotoxicity of **PNPS**, **NPS-H<sub>2</sub>O<sub>2</sub>** and 5'-DFUR under dark. After 3 h incubation, **NPS-H<sub>2</sub>O<sub>2</sub>** and 5'-DFUR exhibited low cytotoxicity even at a high concentration of  $15 \mu\text{M}$  as more than 80% of the tested HeLa and HepG2 cells survived (Fig. 5). On the contrary, **PNPS** demonstrated much higher dark cytotoxicity with an  $\text{IC}_{50}$  value of  $16.6 \mu\text{M}$  and  $14.8 \mu\text{M}$  for HeLa cells and HepG2 cells respectively (Fig. S14 and S15<sup>†</sup>). Taken together, these results illustrated that **PNPS** exhibited enhanced cytotoxicity over commercial 5'-DFUR. For **PNPS**, in addition to the high cytotoxicity under dark conditions, under white light




Fig. 4 (A) The change of DPHA absorbance at 373 nm in the presence of **PNPS** after different durations of white light irradiation. (B) The change of MNAH fluorescence intensity at 535 nm in the presence of **PNPS** after different durations of white light irradiation. The blank bar represents the reaction solution pretreated with  $\text{H}_2\text{O}_2$  for 0.5 h before light irradiation, the red bar represents without  $\text{H}_2\text{O}_2$  pretreatment. (C) Fluorescence imaging showing the  $^1\text{O}_2$  generation of **PNPS** ( $5 \mu\text{M}$ ) in HeLa cells after different treatments using (DCF-DA,  $2 \mu\text{M}$ ) as indicator. The green channel is from DCF-DA ( $\lambda_{\text{ex}} = 488 \text{ nm}$ ,  $\lambda_{\text{em}} = 500\text{--}550 \text{ nm}$ ); the red channel is from **PNPS** ( $\lambda_{\text{ex}} = 635 \text{ nm}$ ,  $\lambda_{\text{em}} = 680\text{--}750 \text{ nm}$ ).




Fig. 3 Fluorescence images of co-localized experiment in HeLa cells. The cells were incubated with **PNPS** for 0.5 h and then incubated with MitoTracker Green for another 0.5 h. (A) MitoTracker Green ( $0.5 \mu\text{M}$ ,  $\lambda_{\text{ex}} = 488 \text{ nm}$ ,  $\lambda_{\text{em}} = 500\text{--}550 \text{ nm}$ ). (B) Prodrug **PNPS** ( $5 \mu\text{M}$ ,  $\lambda_{\text{ex}} = 635 \text{ nm}$ ,  $\lambda_{\text{em}} = 680\text{--}750 \text{ nm}$ ). (C) Overlay of (A) and (B). (D) Intensity correlation plot of stain, the Pearson's correlation factor is 0.965.






Fig. 5 Viability of (A) HeLa, (B) HepG2 and (D) HL7702 cells upon treatment with different concentrations of NPS-H<sub>2</sub>O<sub>2</sub> or PNPS showed under white light irradiation or in dark. (C) Viability of HeLa (black bar) and HepG2 (red bar) cells upon treatment with different concentrations of 5'-DFUR.

illumination, it could generate <sup>1</sup>O<sub>2</sub> and exhibited high phototoxicity to cancer cells. Notably, under white light illumination, the IC<sub>50</sub> value of PNPS towards HeLa and HepG2 cells was 9.32 μM and 8.15 μM respectively (Fig. S14 and 15<sup>†</sup>), which was lower than that of PNPS without light irradiation (Fig. 5A and B). And compare to NPS-H<sub>2</sub>O<sub>2</sub>, PNPS showed enhanced cytotoxicity to cancer cells, due to its chemo-photodynamic combination therapy. However, both PNPS and NPS-H<sub>2</sub>O<sub>2</sub> showed lower cytotoxicity even at a high concentration of 10 μM towards HL-7702 cells as more than 75% of the tested HL-7702 cells survived (Fig. 5D). As contrast, compound NPS exhibited high phototoxicity to HL-7702 cells (Fig. S16<sup>†</sup>), with IC<sub>50</sub> value of 8.50 μM (Fig. S17<sup>†</sup>). These results indicated that the prodrugs PNPS and NPS-H<sub>2</sub>O<sub>2</sub> show low cytotoxicity to normal HL-7702 cells, which may mainly because that PNPS and NPS-H<sub>2</sub>O<sub>2</sub> kept inactivated in HL-7702 cells. Collectively, these results demonstrated that the combination chemo-therapy and PDT provides higher anticancer effect compared to the single therapeutic approach alone.

The propidium iodide (PI) staining experiments were further carried out to demonstrate MTS results. PI, a cell impermeable




Fig. 6 *In vivo* imaging of HCT116 tumor-bearing mice at various time (0, 0.5, 1 h and 2 h) after orthotopic injection of the prodrug PNPS (0.288 mg kg<sup>-1</sup>). 0 h means that the images was captured immediately after injection.




Fig. 7 *In vivo* imaging of HCT116 tumor-bearing mice at various times after intravenous injection of (A) prodrug PNPS (4.31 mg kg<sup>-1</sup>) and (B) saline. Fluorescence images of the internal organs at 25 h post injection after anatomy for prodrug PNPS (C) and saline (D). 0 h means that the images was captured immediately after injection.

dye, only stains dead cells or late apoptotic cells with damaged membrane. As shown in Fig. S18,<sup>†</sup> PNPS-treated HeLa cells incubated under the dark was stained whereas nearly all the cells were stained after they were exposed to white light irradiation. Meanwhile, HL-7702 cells were incubated with PNPS much fewer cells were stained even after white light irradiation. However, when HL-7702 cells were first treated with H<sub>2</sub>O<sub>2</sub> and follow with PNPS, most cells were stained after white light irradiation. Collectively, these results indicate that PNPS achieves lower side effects to normal cells.

Benefit from its NIR fluorescence, the activation of the prodrug PNPS in tumor-bearing mice could be investigated *via in vivo* fluorescence imaging. The nude mice bearing HCT116 xenografts were injected in the tumor site with the prodrug PNPS, and *in vivo* images were obtained at various times. As shown in Fig. 6, NIR fluorescence intensity representing the release of the activated drug, was clearly observed at 0.5 h after the injection of the PNPS, the NIR fluorescence then increased in time-dependent manner. These results indicated that therapeutic prodrug PNPS could be effectively activated in the tumor and could be used for real-time fluorescence monitoring of the therapeutic effect *in vivo*.

We further investigated the activation and bio-distribution of prodrugs PNPS with HCT116 tumor-bearing mice, intravenously injected with PNPS and saline. As shown in Fig. 7A, the obvious fluorescence was seen in the tumor region after treated by prodrug PNPS for 1 h, indicative of the rapid distribution of PNPS *via* the blood circulation and the effective activation of PNPS in tumor. And a significant fluorescence enhancement was observed in tumor as time continued before 12 h post



injection due to the gradual prodrug activation, and it faded out as time further increased, owing to the excretion of the activated drug. In contrast, negligible signals were obtained in the saline-treated mice (Fig. 7B). And during the distribution process of 12 h, **PNPS** had the strongest fluorescence, representing the largest amount of released drug, in the tumor. These results indicated prominent tumor-targeting activation ability of **PNPS**. The tumor-targeting drug release along with fluorescence enhancement could be ascribed to the particularly high  $\text{H}_2\text{O}_2$  concentration in cancer cells. Furthermore, in fluorescence images of the internal organs at 25 h post injection after anatomy, an obvious fluorescence was observed in the tumor, liver and stomach of mice treated by prodrug **PNPS**, and much weaker fluorescence were seen in lung, heart, kidney and spleen (Fig. 7C). Meanwhile, in the control experiments, no obvious fluorescence were observed in the tumor or other internal organs (Fig. 7D). The tumor-targeting ability and the specific drug release in tumor make **PNPS** a promising prodrug to achieve high efficacy and reduced side effects.

## Conclusions

In summary, by conjugating the anticancer drug 5'-DFUR and NIR photosensitizer (**NPS**) via a bisboronate bond, we developed a novel  $\text{H}_2\text{O}_2$ -responsive NIR theranostics prodrug **PNPS**. The phototoxicity and inherent NIR fluorescence of **NPS** and the cytotoxicity of the drug (5'-DFUR) are quenched by the covalent  $\text{H}_2\text{O}_2$ -responsive linker. **PNPS** can be effectively activated by the high concentration of  $\text{H}_2\text{O}_2$  in cancer cells or in tumor as monitored by the turn-on NIR fluorescence. **PNPS** shows enhanced chemotherapy efficiency compare to free 5'-DFUR due to its mitochondrial-targeting ability. Furthermore, it shows remarkably improved and synergistic chemophotodynamic therapeutic effect for cancer cells. More importantly, **PNPS** exhibits higher cytotoxicity to cancer cells than that to normal HL-7702 cells, resulting in lower side effects. Therefore, the prodrug **PNPS** provides a promising platform for specific tumor-activatable drug delivery system, which can be easily monitored by cellular and *in vivo* NIR fluorescence imaging. This study also suggests that the molecular probe design strategy, which combines the key functions of targeting, release, imaging, and treatment within a single agent, may play an important role in cancer diagnosis and therapy.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

This work was supported by the National Natural Science Foundation of China (Grants 21325520, 21521063, 21327009, 21375076, J1210040), the science and technology project of Hunan Province (2016RS2009, 2016WK2002).

## Notes and references

- 1 A. Umar, B. K. Dunn and P. Greenwald, *Nat. Rev. Cancer*, 2012, **12**, 835–848.
- 2 P. E. Goss and A. F. Chambers, *Nat. Rev. Cancer*, 2010, **10**, 871–877.
- 3 X. Li, J. Kim, J. Yoon and X. Chen, *Adv. Mater.*, 2017, **29**, 1606857.
- 4 H. Ju, *Sci. China: Chem.*, 2015, **58**, 438.
- 5 W. Pan, H. Yang, T. Zhang, Y. Li, N. Li and B. Tang, *Anal. Chem.*, 2013, **85**, 6930–6935.
- 6 J. P. Celli, B. Q. Spring, I. Rizvi, C. L. Evans, K. S. Samkoe, S. Verma, B. W. Pogue and T. Hasan, *Chem. Rev.*, 2010, **110**, 2795.
- 7 A. P. Castano, P. Mroz and M. R. Hamblin, *Nat. Rev. Cancer*, 2006, **6**, 535–545.
- 8 X. S. Li, S. Kolemen, J. Yoon and E. U. Akkaya, *Adv. Funct. Mater.*, 2017, **27**, 1604053.
- 9 S. Kolemen, M. Isik, G. M. Kim, D. Kim, H. Geng, M. Buyuktemiz, T. Karatas, X. F. Zhang, Y. Dede, J. Yoon and E. U. Akkaya, *Angew. Chem., Int. Ed.*, 2015, **54**, 5340–5344.
- 10 J. F. Lovell, T. W. B. Liu, J. Chen and G. Zheng, *Chem. Rev.*, 2010, **110**, 2839–2857.
- 11 R. Musiol, M. Serda and J. Polanski, *Curr. Pharm. Des.*, 2011, **17**, 3548–3559.
- 12 Z. Guo, S. Park, J. Yoon and I. Shin, *Chem. Soc. Rev.*, 2014, **43**, 16–29.
- 13 X. Chen, D. Lee, S. Yu, G. Kim, S. Lee, Y. Cho, H. Jeong, K. T. Nam and J. Yoon, *Biomaterials*, 2017, **122**, 130–140.
- 14 N. Li, Z. Yu, W. Pan, Y. Han, T. Zhang and B. Tang, *Adv. Funct. Mater.*, 2013, **23**, 2255–2262.
- 15 H. Eda, K. Fujimoto, S.-i. Watanabe, M. Ura, A. Hino, Y. Tanaka, K. Wada and H. Ishitsuka, *Cancer Chemother. Pharmacol.*, 1993, **32**, 333–338.
- 16 M. Olivo, R. Bhuvaneshwari, S. S. Lucky, N. Dendukuri and P. Soo-Ping Thong, *Pharmaceuticals*, 2010, **3**, 1507–1529.
- 17 W. Zhang, J. Shen, H. Su, G. Mu, J.-H. Sun, C.-P. Tan, X.-J. Liang, L.-N. Ji and Z.-W. Mao, *ACS Appl. Mater. Interfaces*, 2016, **8**, 13332–13340.
- 18 Y. Zhang, F. Huang, C. Ren, L. Yang, J. Liu, Z. Cheng, L. Chu and J. Liu, *ACS Appl. Mater. Interfaces*, 2017, **9**, 13016–13028.
- 19 P. R. Ogilby, *Chem. Soc. Rev.*, 2010, **39**, 3181–3209.
- 20 R. Hilf, *J. Bioenerg. Biomembr.*, 2007, **39**, 85–89.
- 21 L. Rajendran, H. J. Knolker and K. Simons, *Nat. Rev. Drug Discovery*, 2010, **9**, 29–42.
- 22 Z. Yu, W. Pan, N. Li and B. Tang, *Chem. Sci.*, 2016, **7**, 4237–4244.
- 23 S. Fulda, L. Galluzzi and G. Kroemer, *Nat. Rev. Drug Discovery*, 2010, **9**, 447–464.
- 24 Z. Yu, Q. Sun, W. Pan, N. Li and B. Tang, *ACS Nano*, 2015, **9**, 11064–11074.
- 25 C.-J. Zhang, Q. Hu, G. Feng, R. Zhang, Y. Yuan, X. Lu and B. Liu, *Chem. Sci.*, 2015, **6**, 4580–4586.
- 26 M. Z. Ye, X. H. Wang, J. B. Tang, Z. Q. Guo, Y. Q. Shen, H. Tian and W. H. Zhu, *Chem. Sci.*, 2016, **7**, 4958–4965.



- 27 M. Gao, F. Yu, C. Lv, J. Choo and L. Chen, *Chem. Soc. Rev.*, 2017, **46**, 2237–2271.
- 28 J.-Z. Du, X.-J. Du, C.-Q. Mao and J. Wang, *J. Am. Chem. Soc.*, 2011, **133**, 17560–17563.
- 29 Y. Y. Yuan, C. J. Zhang, S. D. Xu and B. Liu, *Chem. Sci.*, 2016, **7**, 1862–1866.
- 30 E.-J. Kim, S. Bhuniya, H. Lee, H. M. Kim, C. Cheong, S. Maiti, K. S. Hong and J. S. Kim, *J. Am. Chem. Soc.*, 2014, **136**, 13888–13894.
- 31 R. Kumar, J. Han, H.-J. Lim, W. X. Ren, J.-Y. Lim, J.-H. Kim and J. S. Kim, *J. Am. Chem. Soc.*, 2014, **136**, 17836–17843.
- 32 Y. Ichikawa, M. Kamiya, F. Obata, M. Miura, T. Terai, T. Komatsu, T. Ueno, K. Hanaoka, T. Nagano and Y. Urano, *Angew. Chem., Int. Ed.*, 2014, **53**, 6772–6775.
- 33 Y. Y. Yuan, C. J. Zhang, M. Gao, R. Y. Zhang, B. Z. Tang and B. Liu, *Angew. Chem., Int. Ed.*, 2015, **54**, 1780–1786.
- 34 G. Zheng, J. Chen, K. Stefflova, M. Jarvi, H. Li and B. C. Wilson, *Proc. Natl. Acad. Sci. U. S. A.*, 2007, **104**, 8989–8994.
- 35 F. P. Kong, Z. Y. Liang, D. R. Luan, X. J. Liu, K. H. Xu and B. Tang, *Anal. Chem.*, 2016, **88**, 6450–6456.
- 36 X. Wu, X. Sun, Z. Guo, J. Tang, Y. Shen, T. D. James, H. Tian and W. Zhu, *J. Am. Chem. Soc.*, 2014, **136**, 3579–3588.
- 37 S. Bhuniya, S. Maiti, E. J. Kim, H. Lee, J. L. Sessler, K. S. Hong and J. S. Kim, *Angew. Chem., Int. Ed.*, 2014, **53**, 4469–4474.
- 38 S. Santra, C. Kaittanis, O. J. Santiesteban and J. M. Perez, *J. Am. Chem. Soc.*, 2011, **133**, 16680–16688.
- 39 L. Yuan, W. Lin, S. Zhao, W. Gao, B. Chen, L. He and S. Zhu, *J. Am. Chem. Soc.*, 2012, **134**, 13510–13523.
- 40 E. W. Miller and C. J. Chang, *Curr. Opin. Chem. Biol.*, 2007, **11**, 620–625.
- 41 Y. Yuan, C.-J. Zhang, S. Xu and B. Liu, *Chem. Sci.*, 2016, **7**, 1862–1866.
- 42 H.-W. Liu, S. Xu, P. Wang, X.-X. Hu, J. Zhang, L. Yuan, X.-B. Zhang and W. Tan, *Chem. Commun.*, 2016, **52**, 12330–12333.

